Adoptive cell therapy (ACT), using either autologous tumour-infiltrating lymphocytes or donor lymphocytes, has proved an effective treatment for some patients with advanced cancers. Can the ability to genetically engineer human lymphocytes for ACT further expand the use of this treatment?
- Steven A. Rosenberg
- Nicholas P. Restifo
- Mark E. Dudley